2022 EULAR Recommendations for ANCA-associated Vasculitis
EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Read ArticleEULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Read ArticleRetrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.
Read ArticleAfter an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr.
Read ArticleAn international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid ar
Read ArticleThe Annals of Rheumatic Disease has published updated multinational, treat-to-target (T2T) recommendations for the treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).
Read ArticleDr. Jack Cush Reviews the News and Journal articles from the past week on RheumNow. This weeks highlights includes insights on scleroderma, myositis, vasculitis and answers the question - does aggressive biologic treatment of psoriasis prevent future psoriatic arthritis?
Read ArticleDr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow. This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.
Read ArticleA research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE).
Read ArticleBearing in mind that renal impairment is among the worst complications of ANCA-associated vasculitis (AAV), researchers have identified four different trajectories of kidney function over time in AAV patients, with implications for personalized treatment, as well as future research.
Read ArticleDespite the encouraging phase II trial results of baricitinib in systemic lupus erythematosus (SLE) patients, two parallel phase III trials have failed to redemonstrate the efficacy of baricitinib in active SLE, thereby halting development of baricitinib in SLE.
Read ArticleA prospective, pragmatic, open-label, randomized trial conducted by the UK National Health Service, studied interventions in patients with carpal tunnel syndrome (CTS) and found no advantage to either CTS corticosteroid injection (CSI) or night splinting (NS) as the initial treatment of CTS.
Read ArticleA small cohort trial of rituximab (RTX) in 29 systemic sclerosis patients showed significantly improved skin sclerosis and lung function after a follow-up of 96 weeks.
Read ArticleA novel trial has shown that combination biologic therapy (guselkumab plus golimumab) to be more effective in ulcerative colitis than either biologic alone.
Read ArticleMost patients with psoriatic arthritis (PsA) failed to achieve low disease activity after switching from one targeted therapy to another, real-world data from Scandinavian registries indicated.
Read ArticleTofacitinib (Xeljanz) in patients with rheumatoid arthritis (RA) stood out among several other biologic and targeted synthetic disease-modifying antirheumatic drugs (sDMARDs) when it came to the incidence of interstitial lung disease (ILD), a retrospective cohort study showed.
Read ArticleA single center cohort study analyzed the outcome and survival of idiopathic inflammatory myositis (IIM) patients and showed good 5 and 10 year survival but showed significant declined 15-25 years post-diagnosis.
Read ArticleIntensity of distance running had no bearing on the prevalence of hip and knee osteoarthritis among participants in recent editions of the Chicago Marathon, researchers reported here.
Read ArticleMuch like the recent ACR Convergence, RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis and especially what to do regarding pre-clinical RA.
Read Article